CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管多类药物及其联合方案已改善总生存期，多发性骨髓瘤仍无法治愈。近期，靶向癌细胞表面抗原的免疫疗法，如嵌合抗原受体（CAR）T 细胞疗法和重定向 T 细胞的双特异性抗体，已获监管批准并显示前所未有的疗效。然而，这些免疫疗法具有不同于骨髓瘤既往治疗的独特作用机制和毒性，因此临床试验和早期用药项目中的经验对于制定针对性的患者管理建议至关重要，尤其是这些药物现已在世界许多地区可及。本文提供专家共识临床实践指南，指导双特异性抗体用于骨髓瘤治疗。国际骨髓瘤工作组也在收集接受此类免疫疗法患者的前瞻性实时数据，以便持续学习和调整临床实践，优化免疫治疗患者管理。
Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall survival. Immunotherapies directed against cancer cell-surface antigens, such as chimeric antigen receptor (CAR) T-cell therapy and T-cell-redirecting bispecific antibodies, have recently received regulatory approvals and shown unprecedented efficacy.
However, these immunotherapies have unique mechanisms of action and toxicities that are different to previous treatments for myeloma, so experiences from clinical trials and early access programmes are essential for providing specific recommendations for management of patients, especially as these agents become available across many parts of the world.
Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The International Myeloma Working Group is also involved in the collection of prospective real-time data of patients treated with such immunotherapies, with the aim of learning continuously and adapting clinical practices to optimise the management of patients receiving immunotherapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
